The pro-angiogenic factor CCN1 enhances the re-endothelialization of biological vascularized matrices in vitro

Cardiovascular Research

Volumn 85, Issue 4, 2010, Pages 806-813

  Bär, Antonia ^a   Dorfman, Suzanne E ^a   Fischer, Philipp ^a   Hilfiker Kleiner, Denise ^a   Cebotari, Serghei ^a   Tudorache, Igor ^a   Suprunov, Marc ^a   Haverich, Axel ^a   Hilfiker, Andres ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

CCN1; Endothelium; Extracellular matrix; Tissue engineering

Indexed keywords

CD31 ANTIGEN; CYSTEINE RICH PROTEIN 61; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LACTIC ACID; LOW DENSITY LIPOPROTEIN; VON WILLEBRAND FACTOR;

ARTICLE; BIOREACTOR; BLOOD VESSEL; CELL ADHESION; CELL CULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENDOTHELIUM CELL; FLUORESCENCE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METABOLISM; PERFUSION; PH; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TRANSPORT; TISSUE ENGINEERING; UMBILICAL CORD BLOOD;

CELL ADHESION; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; CYSTEINE-RICH PROTEIN 61; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; FETAL BLOOD; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; TISSUE ENGINEERING;

EID: 76749085198     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp370     Document Type: Article

References (38)

1. WHO. Fact Sheet No 317.
2. Bär A, Haverich A, Hilfiker A. Cardiac tissue engineering: 'reconstructing the motor of life'. Scand J Surg 2007;96:154-158.
3. Korecky B, Hai CM, Rakusan K. Functional capillary density in normal and transplanted rat hearts. Can J Physiol Pharmacol 1982;60:23-32.
4. Birla RK, Borschel GH, Dennis RG, Brown DL. Myocardial engineering in vivo: formation and characterization of contractile, vascularized three-dimensional cardiac tissue. Tissue Eng 2005;11:803-813.
5. Carrier RL, Rupnick M, Langer R, Schoen FJ, Freed LE, Vunjak-Novakovic G. Effects of oxygen on engineered cardiac muscle. Biotechnol Bioeng 2002;78: 617-625.
6. Kofidis T, Lenz A, Boublik J, Akhyari P, Wachsmann B, Mueller-Stahl K et al. Pulsatile perfusion and cardiomyocyte viability in a solid three-dimensional matrix. Biomaterials 2003;24:5009-5014.
7. Radisic M, Yang L, Boublik J, Cohen RJ, Langer R, Freed LE et al. Medium perfusion enables engineering of compact and contractile cardiac tissue. Am J Physiol Heart Circ Physiol 2004;286:H507-H516.
8. Freed LE, Vunjak-Novakovic G. Microgravity tissue engineering. In Vitro Cell Dev Biol Anim 1997;33:381-385.
9. Chin K, Khattak SF, Bhatia SR, Roberts SC. Hydrogel-perfluorocarbon composite scaffold promotes oxygen transport to immobilized cells. Biotechnol Prog 2008;24: 358-366.
10. Iyer RK, Radisic M, Cannizzaro C, Vunjak-Novakovic G. Synthetic oxygen carriers in cardiac tissue engineering. Artif Cells Blood Substit Immobil Biotechnol 2007;35: 135-148. (Pubitemid 46324172)
11. Nieuwoudt MJ, Moolman SF, Van Wyk KJ, Kreft E, Olivier B, Laurens JB et al. Hep-atocyte function in a radial-flow bioreactor using a perfluorocarbon oxygen carriers. Artif Organs 2005;29:915-918.
12. Radisic M, Park H, Chen F, Salazar-Lazzaro JE, Wang Y, Dennis R et al. Biomimetic approach to cardiac tissue engineering: oxygen carriers and channeled scaffolds. Tissue Eng 2006;12:2077-2091.
13. Eschenhagen T, Zimmermann WH. Engineering myocardial tissue. Circ Res 2005; 97:1220-1231.
14. Morritt AN, Bortolotto SK, Dilley RJ, Han X, Kompa AR, McCombe D et al. Cardiac tissue engineering in an in vivo vascularized chamber. Circulation 2007; 115:353-360.
15. Caspi O, Lesman A, Basevitch Y, Gepstein A, Arbel G, Habib IH et al. Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. Circ Res 2007;100:263-272.
16. Schultheiss D, Gabouev AI, Kaufmann PM, Schlote N, Mertsching H, Haverich A et al. Biological vascularized matrix (BioVaM): a new method for solving the perfusion problems in tissue engineering. Urologe A 2004;43: 1223-1228.
17. Mertsching H, Walles T, Hofmann M, Schanz J, Knapp WH. Engineering of a vascularized scaffold for artificial tissue and organ generation. Biomaterials 2005;26:6610-6617.
18. Babic AM, Chen CC, Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 1999;19:2958-2966.
19. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998;95:6355-6360.
20. Grote K, Salguero G, Ballmaier M, Dangers M, Drexler H, Schieffer B. The angio-genic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration. Blood 2007;110:877-885.
21. Kireeva ML, Lam SC, Lau LF. Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphav-beta3. J Biol Chem 1998;273:3090-3096.
22. Kireeva ML, Latinkic BV, Kolesnikova TV, Chen CC, Yang GP, Abler AS et al. Cyr61 and Fisp12 are both ECM-associated signaling molecules: activities, metabolism, and localization during development. Exp Cell Res 1997;233: 63-77.
23. Kireeva ML, Mo FE, Yang GP, Lau LF. Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol 1996;16:1326-1334.
24. Kolesnikova TV, Lau LF. Human CYR61-mediated enhancement of bFGF-induced DNA synthesis in human umbilical vein endothelial cells. Oncogene 1998;16: 747-754.
25. Brigstock DR. The CCN family: a new stimulus package. J Endocrinol 2003;178: 169-175.
26. Chen Y, Du XY. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem 2007;100:1337-1345.
27. Murohara T, Ikeda H, Duan J, Shintani S, Sasaki K, Eguchi H et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovasculariza-tion. J Clin Invest 2000;105:1527-1536.
28. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000;95:3106-3112.
29. Voyta JC, Via DP, Butterfield CE, Zetter BR. Identification and isolation of endo-thelial cells based on their increased uptake of acetylated-low density lipoprotein. J Cell Biol 1984;99:2034-2040.
30. Doran PM. Bioprocess Engineering Principles. San Diego, CA: Academic Press Inc.; 1999.
31. Lau LF, Nathans D. Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: coordinate regulation with c-fos or c-myc. Proc Natl Acad Sci USA 1987;84:1182-1186.
32. O'Brien TP, Yang GP, Sanders L, Lau LF. Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol 1990;10:3569-3577.
33. Yang GP, Lau LF. Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ 1991;2:351-357.
34. Fataccioli V, Abergel V, Wingertsmann L, Neuville P, Spitz E, Adnot S et al. Stimulation of angiogenesis by Cyr61 gene: a new therapeutic candidate. Hum Gene Ther 2002;13:1461-1470.
35. Hilfiker A, Hilfiker-Kleiner D, Fuchs M, Kaminski K, Lichtenberg A, Rothkotter HJ et al. Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis and its regulation by angiotensin II. Circulation 2002;106: 254-260.
36. Hilfiker-Kleiner D, Kaminski K, Kaminska A, Fuchs M, Klein G, Podewski E et al. Regulation of proangiogenic factor CCN1 in cardiac muscle: impact of ischemia, pressure overload, and neurohumoral activation. Circulation 2004;109: 2227-2233.
37. Chen N, Chen CC, Lau LF. Adhesion of human skin fibroblasts to Cyr61 is mediated through integrin alpha 6beta 1 and cell surface heparan sulfate proteo-glycans. J Biol Chem 2000;275:24953-24961.
38. Schober JM, Chen N, Grzeszkiewicz TM, Jovanovic I, Emeson EE, Ugarova TP et al. Identification of integrin alpha(M)beta(2) as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions. Blood 2002;99:4457-4465.